Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schistosomiasis
Conditions
Schistosomiasis
Trial Timeline
Sep 3, 2019 → Feb 21, 2020
NCT ID
NCT04115072About Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1
Praziquantel 600Mg Oral Tablet x 5 + Praziquantel 600Mg Oral Tablet x 1 is a phase 2/3 stage product being developed by Merck for Schistosomiasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04115072. Target conditions include Schistosomiasis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04115072 | Phase 2/3 | Completed |
Competing Products
3 competing products in Schistosomiasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Biltricide (racemate praziquantel) oral tablets + Racemate Praziquantel ODT + Levo Praziquantel ODT | Merck | Phase 2 | 52 |
| L-PZQ ODT 50 mg/kg + Biltricide® + L-PZQ ODT 60 mg/kg | Merck | Phase 3 | 77 |
| praziquantel | Hikma Pharmaceuticals | Phase 3 | 72 |